US EditionApellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High
Biogen’s $5.6 billion acquisition of Apellis includes contingent payments tied to Syfovre sales, with combined drug sales reaching $689 million in 2025, boosting growth in immunology and rare diseases.
- On Tuesday, Biogen announced it will acquire Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, valuing the company at $41 per share, representing a premium of about 140% to the stock's last close.
- Facing competition from biosimilars to its multiple sclerosis drugs Tysabri, Tecfidera, and Spinraza, Biogen is bolstering its rare-disease portfolio through the acquisition. The deal accelerates Biogen's entry into nephrology and kidney disease treatments.
- Apellis brings two FDA-approved therapies to Biogen's portfolio: Empaveli and Syfovre. Combined net sales for these products reached $689 million in 2025 and are expected to grow at a mid-to-high teens rate through 2028.
- Shareholders remain eligible for up to an additional $4 per share through contingent value rights tied to Syfovre sales milestones. Payments include $2 for annual sales reaching $1.5 billion and $2 for crossing the $2 billion threshold.
- Biogen CEO Chris Viehbacher stated, "This acquisition immediately advances Biogen's ongoing transformation," expecting a "significant proportion" of Apellis employees to join the company. The deal positions Biogen to strengthen its immunology and rare-disease capabilities.
17 Articles
17 Articles
Why Biogen Stock Sank While the Market Soared on Thursday
Key PointsIf all goes as planned, it'll soon be the owner of Apellis Pharmaceuticals.The company's asset-to-be has two commercialized medicines on the market based on the same active ingredient.10 stocks we like better than Biogen › Bullishness was in the air on the stock market on Tuesday, but you'd hardly know that from the performance of Biogen (NASDAQ: BIIB). The healthcare sector mainstay saw its share price slump by over 2% that trading se…
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead
Quick Read State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) returned +22.20% over 12 months and is market cap weighted with its top 10 holdings comprising 50% of assets. Interest rate cuts and increased biotech M&A activity driven by Big Pharma’s need for pipeline replacement, combined with AI’s abil…
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
